Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2025.02.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potent P2Y12 inhibitors versus clopidogrel in cancer patients undergoing percutaneous coronary intervention.
Can J Cardiol
March 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Patients with cancer undergoing percutaneous coronary intervention (PCI) experience higher risk of both ischemic and bleeding events. The aim of this study is to assess ischemic and bleeding risks after PCI in cancer patients treated with potent P2Y12 inhibitors (P2Y12i; prasugrel and ticagrelor), compared to clopidogrel.
Methods: Consecutive cancer patients undergoing PCI at a tertiary centre between 2012 and 2022 and discharged on P2Y12i were included.
Ticagrelor Monotherapy Following Short-Term DAPT in ACS Undergoing PCI: A Systematic Review and Meta-Analysis.
Catheter Cardiovasc Interv
February 2025
University of Miami, Division of Cardiovascular Medicine, Miami, Florida, USA.
Background: Dual antiplatelet therapy (DAPT) for 1 year after acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is the standard of care. However, it is associated with a higher incidence of bleeding events. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the safety and efficacy of short-term DAPT.
View Article and Find Full Text PDFTicagrelor Versus Clopidogrel in Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention for Acute Coronary Syndrome in Chronic Kidney Disease.
Am J Cardiol
February 2025
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Objective This study aimed to compare the safety and efficacy of ticagrelor and clopidogrel in reducing major adverse cardiovascular events (MACE) among patients undergoing percutaneous coronary intervention (PCI) for chronic coronary disease. Additionally, secondary endpoints, including adverse events such as major bleeding, minor bleeding, and dyspnea, were assessed to evaluate the overall safety profile of both antiplatelet therapies. Methodology A prospective cohort study was conducted at Kuwait Teaching Hospital, Peshawar, Pakistan, enrolling 300 patients (150 receiving ticagrelor and 150 receiving clopidogrel) from July 2023 to June 2024.
View Article and Find Full Text PDFDe-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systemic Review and Individual Patient Data Meta-Analysis of Randomized Clinical Trials.
Ann Intern Med
February 2025
Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (Y.-J.L., S.-H.L., S.-J.L., S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., M.-K.H.).
Background: The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive.
Purpose: To compare the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT from randomized clinical trials in patients with ACS.
Data Sources: PubMed, EMBASE, Scopus, and ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!